• The global Pleural Effusion Drug Market is poised for substantial growth through 2032, registering a CAGR of 8.2% from 2025 to 2032.
• Recurrent and malignant pleural effusions, often resulting from chronic illnesses and cancer, are contributing to the increasing need for both drug-based and adjunctive therapies.
• The market benefits from progress in targeted drug development, broader application of intrapleural therapies, and innovation in supportive care medications.
• Growth in healthcare infrastructure, development of oncology-focused treatment pathways, and rising investments in rare disease management are expected to further strengthen market performance, especially in emerging markets.
